Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virus

17 May 2021

Abstract excerpt

The emerging variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in pandemic call for the urgent development of universal corona virus disease 2019 (COVID-19) vaccines which could be effective for both wild-type SARS-CoV-2 and mutant strains. In the current study, we formulated protein subunit vaccines with AS03 adjuvant and recombinant proteins of S1 subunit of SARS-CoV-2 (S1-WT) and S1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Peripheral Neuropathies and Disorders
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34226895
DOI: 10.1002/mco2.72

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virusPMID 34226895Read ↗

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2Semantic proximity Read ↗

DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in miceSemantic proximity Read ↗

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged MiceSemantic proximity Read ↗

Second Boost of Omicron SARS-CoV-2 S1 Subunit Vaccine Induced Broad Humoral Immune Responses in Elderly MiceSemantic proximity Read ↗

Pan-recombinant vaccines based on the consensus sequence of severe acute respiratory syndrome coronavirus-2 spike proteinSemantic proximity Read ↗

Preclinical Study of DNA Vaccines Targeting SARS-CoV-2Semantic proximity Read ↗

Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2Semantic proximity Read ↗

Preclinical Immunological Evaluation of an Intradermally Administered Heterologous Vaccine Against SARS-CoV-2 VariantsSemantic proximity Read ↗

Neutralizing antibody-independent immunity to SARS-CoV-2 in Syrian hamsters and human ACE-2 transgenic mice immunized with a RBD/Nucleocapsid fusion proteinSemantic proximity Read ↗

Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal modelSemantic proximity Read ↗

SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigenSemantic proximity Read ↗

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.